Affimed prices public offering to finance NK cell trials
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.
Catalent swallows VMIC Ltd
Catalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction.
AXA launches 440 m private equity healthcare strategy
AXA IM Alts, has launched a Global Health Strategy following a 18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector.
Bayer Leaps to invests 1.3bn externally
German Bayer AG has announced it will channel at least 1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’.
Avantium closes financing for FDCA plant
Novo Holdings co-leads 40m Qure.ai financing
Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad
XNK Therapeutics AB raises 12.75m
XNK Therapeutics AB has secured a private placement of 12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma.
Sanofi and IGM Biosciences Inc. in $6.15bn deal
Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met.
CSL Behring files for MAA of haemophilia B gene therapy
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.